It is crucial to verify the active ingredient in retatrutide products, ensuring its presence, purity, and potency
Jrgen Harreiter: has participated in meetings sponsored by, received speaker/consultancy honoraria or travel funding from Novo Nordisk, Sanofi, Novartis, Eli Lilly, Boehringer-Ingelheim
The science behind Akkermansia and GLP-1 is not made up
Ongoing support from both your healthcare provider and your chosen supplier can help you make informed decisions, manage any adverse effects, and optimize your treatment outcomes
To do this, payers need to assess the long-term ROI of GLP-1s, including the benefits of reduced spend on high-cost comorbidities
Reduction of prevalence of patients meeting the criteria for metabolic syndrome with tirzepatide: a post hoc analysis from the SURPASS Clinical Trial Program